EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study

Mariano Marrodan iD, María A Piedrabuena, María A Zarate, Sofía Rodríguez Murúa, Ezequiel I Surace iD, Mauricio F Farez, Marcela P Fiol, María C Ysrraelit, Jorge Correale

Annals of Clinical and Translational Neurology · 2025-08 · 12 (8) · 1566-1574

DOI: 10.1002/acn3.70095 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.06.2025. Verfasst von Mariano Marrodan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Neurología, Fleni, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Rituximab, Neuromyelitis Optica, Aquaporin 4, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy. However, a subset of patients exhibits treatment refractoriness. Our objective is to investigate factors associated with treatment refractoriness in AQP4‐IgG‐positive NMOSD patients treated with rituximab.

Methods

This retrospective cohort study included 54 AQP4‐IgG‐positive NMOSD patients treated with rituximab between 2006 and 2023. Clinical, imaging, and genetic data were analyzed. Treatment failure was defined as at least one relapse occurring after 6 months of rituximab initiation. Statistical analyses included multivariate analyses of covariance (MANCOVA) and Cox regression to identify independent predictors of treatment failure.

Results

Among the 54 patients (82.5% female, median age 45 years, range: 34–54.5), 12 (22.2%) exhibited rituximab treatment failure. The presence of asymptomatic lesions during follow‐up was significantly associated with treatment failure ( p = 0.02) and emerged as an independent predictor in MANCOVA (Wilks' Lambda = 0.01, F = 20.5, η 2 = 0.357, p < 0.001). These lesions also increased the risk of clinical relapses (HR = 25.9, 95% CI = 3.09–218, p < 0.01). Other variables, including age, sex, baseline EDSS, and persistent gadolinium enhancement, were not significantly associated with treatment failure. Genetic analysis of the FCGR3A‐V158F polymorphism did not reveal a significant relationship with treatment outcomes.

Interpretation

Asymptomatic lesions during rituximab treatment are a strong predictor of therapeutic failure in AQP4‐IgG‐positive NMOSD patients. Early identification of these lesions could guide clinicians in optimizing treatment strategies, including transitioning to alternative therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabNeuromyelitis OpticaAquaporin 4Immunologic FactorsHumansFemaleMaleMiddle AgedAdultRetrospective StudiesImmunoglobulin GAutoantibodiesCohort StudiesTreatment Failure

Stichwörter der Autor:innen

NMOSDneuromyelitis optica spectrum disordersrituximab

Substanzen

RituximabAquaporin 4Immunologic FactorsAQP4 protein, humanImmunoglobulin GAutoantibodies

Autor:innen und Institutionen

  • Departamento de Neurología, Fleni, Buenos Aires, Argentina.
  • Centro de Investigación en Enfermedades Neuroinmunológicas (CIEN), Fleni, Buenos Aires, Argentina.
  • Laboratorio de Enfermedades Neurodegenerativas, Instituto de Neurociencias Fleni-CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Buenos Aires, Argentina.
  • Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), CONICET/Universidad de Buenos Aires, Buenos Aires, Argentina.

ORCID-Profile: Mariano Marrodan, Ezequiel I Surace

Förderung

  • AstraZeneca

Zitieren

APA

Marrodan, M., Piedrabuena, M. A., Zarate, M. A., Rodríguez Murúa, S., Surace, E. I., Farez, M. F., Fiol, M. P., Ysrraelit, M. C., & Correale, J. (2025). Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study. Annals of Clinical and Translational Neurology, 12(8), 1566-1574. https://doi.org/10.1002/acn3.70095

Vancouver

Marrodan M, Piedrabuena MA, Zarate MA, Rodríguez Murúa S, Surace EI, Farez MF, et al. Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study. Annals of Clinical and Translational Neurology. 2025;12(8):1566-1574. doi:10.1002/acn3.70095

BibTeX
@article{Marrodan2025,
  author = {Marrodan, Mariano and Piedrabuena, María A and Zarate, María A and Rodríguez Murúa, Sofía and Surace, Ezequiel I and Farez, Mauricio F and Fiol, Marcela P and Ysrraelit, María C and Correale, Jorge},
  title = {Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {8},
  pages = {1566--1574},
  doi = {10.1002/acn3.70095}
}
Kostenlos starten →